NCT06572553View on ClinicalTrials.gov

Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 1, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions
Age-Related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Interventions
DRUG

Faricimab

Faricimab (faricimab-svoa; Vabysmo), a bispecific antibody that inhibits both VEGF-A and Ang-2, was developed by Roche/Genentech, and dual-pathway inhibition may provide stronger and longer-lasting efficacy in the treatment of retinal vascular disease relative to anti-VEGF therapy alone.

Trial Locations (1)

310000

RECRUITING

2 nd Affiliated Hospital, School of Medicine, Zhejiang University, China, Hanzhou

All Listed Sponsors
lead

Second Affiliated Hospital, School of Medicine, Zhejiang University

OTHER